Shield Therapeutics PLC Appointment of Non-Executive Director (0741K)
April 06 2018 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 0741K
Shield Therapeutics PLC
06 April 2018
Shield Therapeutics plc
("Shield" or the "Company")
Appointment of Non-Executive Director
London, UK, 6 April 2018: Shield Therapeutics plc (LSE:STX), a
commercial stage, pharmaceutical company with an initial focus on
addressing iron deficiency, is pleased to announce the appointment
of Rolf Hoffmann, as a Non-Executive Director of the Company with
immediate effect. Mr Hoffmann is currently Chairman of Biotest AG,
sits on the Board of Directors of the large European biotechnology
company Genmab AG and is a Director of San Francisco-based
Trigemina Inc.
Rolf brings to Shield over 30 years of international
pharmaceutical experience having served in several senior roles in
the industry, most recently 12 years with Amgen as Senior Vice
President of Commercial Operations for the United States, and
before that as SVP International and Europe. He started his
pharmaceutical career at Eli Lilly as a sales representative,
progressing to senior positions including President of Latin
America operations and General Manager in Germany. Rolf holds an
MBA from the University of North Carolina, a master's degree from
the University of Cologne and is Adjunct Professor at UNC
Kenan-Flagler Business School.
Andrew Heath, Chairman of Shield Therapeutics, said: "I am
delighted to welcome Rolf to the Board of Shield Therapeutics. His
extensive experience and knowledge of the pharmaceutical industry
and its key stakeholders in major markets will be helpful in
defining the Company's future strategy and we look forward to Rolf
playing a full and active role in these discussions and
beyond."
Regulatory Disclosures
The following disclosures are required regarding Rolf's
appointment pursuant to Schedule Two paragraph (g) of the AIM Rules
for Companies:
Full name and age: Rolf Karl Heinz Hoffmann, aged 58
Schedule of directorships and previous directorships (resigned
within the last five years):
Current Directorships Former Directorships
Amgen Australia Pty
Biotest AG Limited
Amgen (Middle East)
EUSA FZ LCC
Amgen (Middle East)
Genmab AG FZ LLC
German-American Heritage Amgen (New Zealand)
Foundation Limited
Amgen (New Zealand)
NavBio AG Limited
Stada AG Amgen AB Norge
Amgen Australia Pty
Trigemeninia Inc. Limited
US Health Leadership Amgen Australia Pty
Council Limited New Zealand
Amgen Europe B.V., Israel
World Anti-Doping Agency Branch
Amgen Filial AF Amgen
Aktiebolag, Sverige
Amgen Inc.
Amgen Inc.
Amgen Latin America
Services, S.A. de C.V.
Amgen Latin America
Services, S.A. de C.V.
Amgen Mexico, S.A. de
C.V.
Amgen Romania srl
Amgen S.p.A.
Amgen Singapore Pte,
Ltd.
Amgen South Eastern
Europe Operations S.r.l.
Amgen Switzerland AG
Luzern Podruznica Ljubljana
Amgen Switzerland AG
Rigas filiale
Amgen Switzerland AG
Rigas filiale
Amgen Switzerland AG
Slovakia
Amgen Switzerland AG
Viliniaus filialas
Amgen Switzerland AG
Viliniaus filialas
Amgen Technology Private
Limited
Amgen Technology Private
Limited
Amgen USA Inc.
Amgen USA Inc.
Immunex Corporation
Immunex Corporation
Immunex Rhode Island
Corporation
Immunex Rhode Island
Corporation
Tularik Limited
No further disclosure is required under AIM Rule 17 and
paragraph (g) to Schedule Two of the AIM Rules with respect to Rolf
Hoffmann.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Dr Karl Keegan, Chief Financial Officer
Fleur Wood, Director, Investor Relations
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker
+44 (0)207 418 8900
Peel Hunt LLP
James Steel/ Dr Christopher Golden
Financial PR Advisor
+44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering
innovative specialty pharmaceuticals to address patients' unmet
medical needs. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of IDA in adult patients
with IBD which has exclusive IP rights until the mid-2030's. For
more information please visit www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGUGDSRUGBGIL
(END) Dow Jones Newswires
April 06, 2018 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024
